SCHEMBL2350226

SCHEMBL2350226

CCS(=O)(=O)c1ccc2oc(Nc3ccc(C)c(Nc4ncc(-c5ccncc5)o4)c3)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
NPC1 O15118 3/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
MAPT P10636 5/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
FLT1 P17948 2/20 0.51
FLT4 P35916 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348479 0.86 FLT1 (0.46) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL2341934 0.84 IMPDH2 (0.44) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL2346702 0.84 KIT (0.50) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL544079 0.83 NPC1 (0.54) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL2346880 0.79 KIT (0.50) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL2346767 0.79 IMPDH2 (0.44) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL544406 0.76 IMPDH2 (0.62) FLT1FLT4KDR
SCHEMBL4597289 0.75 FLT1 (0.40) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL2342462 0.74 NPC1 (0.52) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL543854 0.74 IMPDH2 (0.56) FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361624-A1 Oxazole derivatives and their use as tyrosine kinase inhibitors AB Science (FR) 2011-08-31 EP claimed
US-20080242704-A1 Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors AB SCIENCE 2008-10-02 US claimed
EP-1874305-B1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2014-08-27 EP disclosed
EP-1874305-B1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2014-08-27 EP disclosed
US-8658659-B2 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE (FR) 2014-02-25 US disclosed
US-8658659-B2 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE (FR) 2014-02-25 US disclosed
US-8658659-B2 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE (FR) 2014-02-25 US disclosed
US-20120108616-A1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE 2012-05-03 US disclosed
US-20120108616-A1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE 2012-05-03 US disclosed
US-20120108616-A1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE 2012-05-03 US disclosed
EP-2361624-A1 Oxazole derivatives and their use as tyrosine kinase inhibitors AB Science (FR) 2011-08-31 EP disclosed
US-20080242704-A1 Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors AB SCIENCE 2008-10-02 US disclosed
US-20080242704-A1 Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors AB SCIENCE 2008-10-02 US disclosed
US-20080242704-A1 Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors AB SCIENCE 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242704-A1 Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors KIT, TYRO3, LCK RAB9A 3284/4885SMN1; SMN2 3607/4885NPC1 3811/4885
US-20120108616-A1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS KIT, FLT3, LTK RAB9A 3492/4885SMN1; SMN2 3683/4885NPC1 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.